MTHFD1 is a genetic interactor of BRD4 and links folate metabolism to transcriptional regulation

The histone acetyl-reader BRD4 is an important regulator of chromatin structure and transcription, yet factors modulating its activity have remained elusive. Here we describe two complementary screens for genetic and physical interactors of BRD4, which converge on the folate pathway enzyme MTHFD1. We show that a fraction of MTHFD1 resides in the nucleus, where it is recruited to distinct genomic loci by direct interaction with BRD4. Inhibition of either BRD4 or MTHFD1 results in similar changes in nuclear metabolite composition and gene expression, and pharmacologic inhibitors of the two pathways synergize to impair cancer cell viability in vitro and in vivo. Our finding that MTHFD1 and other metabolic enzymes are chromatin-associated suggests a direct role for nuclear metabolism in the control of gene expression.

[1]  S. Spicuglia.  Faculty of 1000 evaluation for GENE SILENCING. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. , 2018 .

[2]  Christopher J. Ott,et al.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.

[3]  T. Abel,et al.  ACETYL-COA SYNTHETASE REGULATES HISTONE ACETYLATION AND HIPPOCAMPAL MEMORY , 2017, Nature..

[4]  Joshua D Rabinowitz,et al.  One-Carbon Metabolism in Health and Disease. , 2017, Cell metabolism.

[5]  Przemyslaw Stempor,et al.  SeqPlots - Interactive software for exploratory data analyses, pattern discovery and visualization in genomics , 2016, Wellcome open research.

[6]  Christoph Bock,et al.  Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. , 2016, Nature chemical biology.

[7]  P. Stover,et al.  MTHFD1 regulates nuclear de novo thymidylate biosynthesis and genome stability. , 2016, Biochimie.

[8]  M. Beato,et al.  ADP-ribose–derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling , 2016, Science.

[9]  Howard Y. Chang,et al.  Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. , 2016, Molecular cell.

[10]  M. Cole.  Faculty Opinions recommendation of DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. , 2016 .

[11]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[12]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[13]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[14]  B. Göttgens,et al.  Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells , 2015, Science.

[15]  Dennis L. Buckley,et al.  Selective Target Protein Degradation via Phthalimide Conjugation , 2015 .

[16]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[17]  Johannes Zuber,et al.  Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis , 2015, Nature Communications.

[18]  M. Brosnan,et al.  Nuclear Enrichment of Folate Cofactors and Methylenetetrahydrofolate Dehydrogenase 1 (MTHFD1) Protect de Novo Thymidylate Biosynthesis during Folate Deficiency* , 2014, The Journal of Biological Chemistry.

[19]  A. Quinlan.  BEDTools: The Swiss‐Army Tool for Genome Feature Analysis , 2014, Current protocols in bioinformatics.

[20]  Shuifang Zhu,et al.  Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads , 2014, BMC Bioinformatics.

[21]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[22]  A. Anderson,et al.  Antifolate agents: a patent review (2010 – 2013) , 2014, Expert opinion on therapeutic patents.

[23]  P. Johnston,et al.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.

[24]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[25]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[26]  Christopher J. Ott,et al.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.

[27]  G. Casari,et al.  A reversible gene trap collection empowers haploid genetics in human cells , 2013, Nature Methods.

[28]  Anne E Carpenter,et al.  The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signaling , 2013, Nature.

[29]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[30]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[31]  K. Bennett,et al.  Combining filter-aided sample preparation and pseudoshotgun technology to profile the proteome of a low number of early passage human melanoma cells. , 2013, Journal of proteome research.

[32]  S. Lim,et al.  Elucidating the temporal dynamics of chromatin-associated protein release upon DNA digestion by quantitative proteomic approach. , 2012, Journal of proteomics.

[33]  Marc D. Perry,et al.  ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia , 2012, Genome research.

[34]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[35]  Qiang Zhou,et al.  RNA polymerase II elongation control. , 2012, Annual review of biochemistry.

[36]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[37]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[38]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[39]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[40]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[41]  Carla P. Guimarães,et al.  Global gene disruption in human cells to assign genes to phenotypes by deep sequencing , 2011, Nature Biotechnology.

[42]  Karl Mechtler,et al.  General statistical modeling of data from protein relative expression isobaric tags. , 2011, Journal of proteome research.

[43]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[44]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[45]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[46]  David S. Wishart,et al.  MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data , 2010, Nucleic Acids Res..

[47]  Carla P. Guimarães,et al.  Haploid Genetic Screens in Human Cells Identify Host Factors Used by Pathogens , 2009, Science.

[48]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[49]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[50]  Leah Barrera,et al.  A high-resolution map of active promoters in the human genome , 2005, Nature.

[51]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[52]  H. Berman,et al.  Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .